EnGeneIC

EnGeneIC is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapeutics using its proprietary EnGeneIC Dream Vector (EDV) nanocell technology. Founded in 2001 by Dr. Jennifer MacDiarmid and Dr. Himanshu Brahmbhatt, EnGeneIC has pioneered a unique approach to cancer treatment that combines targeted drug delivery with immunotherapy. The company's EDV nanocell is a first-in-class Antibody Nanocell Drug Conjugate (ANDC) platform capable of delivering various therapeutic payloads directly to cancer cells while simultaneously stimulating the patient's immune system.

The EDV technology enables the delivery of potent chemotherapeutic agents inside cancer cells, effectively overcoming drug resistance mechanisms. Unlike traditional antibody-drug conjugates, the EDV nanocell delivers a large payload of cytotoxic drugs directly into the cancer cell, enhancing treatment precision and minimizing damage to healthy tissues. This approach has shown promising results, particularly for patients with advanced pancreatic ductal adenocarcinoma (PDAC) who have exhausted other treatment options.

In December 2023, EnGeneIC received Fast Track designation from the US Food and Drug Administration (FDA) for its pancreatic cancer therapeutic, highlighting the potential of its EDV-based ANDC in addressing the urgent needs of patients with metastatic PDAC. The company is currently conducting Phase IIa clinical trials in Australia and the US for patients with intractable, low-survival cancers, including metastatic pancreatic cancer.

EnGeneIC's EDV nanocell technology has demonstrated minimal toxicity, with over 1,300 doses administered to 130 end-stage cancer patients. The company's approach aims to provide a more effective and less toxic alternative to traditional cancer treatments, potentially offering hope to patients who have failed all other treatment options.